KR100552991B1 - Extraction and Purification of Active Active Ingredients from Jinkyo and Herbal Medicine Compositions Containing the Extracts - Google Patents

Extraction and Purification of Active Active Ingredients from Jinkyo and Herbal Medicine Compositions Containing the Extracts Download PDF

Info

Publication number
KR100552991B1
KR100552991B1 KR1019980060437A KR19980060437A KR100552991B1 KR 100552991 B1 KR100552991 B1 KR 100552991B1 KR 1019980060437 A KR1019980060437 A KR 1019980060437A KR 19980060437 A KR19980060437 A KR 19980060437A KR 100552991 B1 KR100552991 B1 KR 100552991B1
Authority
KR
South Korea
Prior art keywords
weight
extract
filtrate
extraction
water
Prior art date
Application number
KR1019980060437A
Other languages
Korean (ko)
Other versions
KR20000043996A (en
Inventor
곽의종
한창균
이강진
이해인
김택수
이성재
조용백
김대기
Original Assignee
에스케이케미칼주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에스케이케미칼주식회사 filed Critical 에스케이케미칼주식회사
Priority to KR1019980060437A priority Critical patent/KR100552991B1/en
Publication of KR20000043996A publication Critical patent/KR20000043996A/en
Application granted granted Critical
Publication of KR100552991B1 publication Critical patent/KR100552991B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/51Gentianaceae (Gentian family)
    • A61K36/515Gentiana
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • A61K2236/33Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30Extraction of the material
    • A61K2236/39Complex extraction schemes, e.g. fractionation or repeated extraction steps

Abstract

본 발명은 진교로부터 유효 활성 성분의 추출·정제 방법과 그 추출물을 함유한 생약 조성물에 관한 것으로서, 더욱 상세하게는 알콜 수용액 및 비극성 용매를 이용하여 한약재인 진교로부터 유효 활성 성분을 효율적으로 추출할 수 있는 방법과 그 추출물을 함유하는 소염 진통제 등의 생약 조성물에 관한 것이다.The present invention relates to a method for extracting and purifying an active ingredient from orthodontics, and to a herbal composition containing the extract. More specifically, the active active ingredient can be efficiently extracted from orthodontics, which is a herbal medicine, using an aqueous alcohol solution and a nonpolar solvent. The present invention relates to herbal compositions such as anti-inflammatory analgesics and methods containing the extracts.

Description

진교로부터 유효 활성 성분의 추출·정제 방법과 그 추출물을 함유한 생약 조성물Extraction and Purification Method of Active Active Ingredients from Jinkyo Bridge

본 발명은 진교로부터 유효 활성 성분의 추출·정제 방법과 그 추출물을 함유한 생약 조성물에 관한 것으로서, 더욱 상세하게는 알콜 수용액 및 비극성 용매를 이용하여 한약재인 진교로부터 유효 활성 성분을 효율적으로 추출할 수 있는 방법과 그 추출물을 함유하는 소염 진통제 등의 생약 조성물에 관한 것이다.The present invention relates to a method for extracting and purifying an active ingredient from orthodontics, and to a herbal composition containing the extract. More specifically, the active active ingredient can be efficiently extracted from orthodontics, which is a herbal medicine, using an aqueous alcohol solution and a nonpolar solvent. The present invention relates to herbal compositions such as anti-inflammatory analgesics and methods containing the extracts.

진교는 우리나라 전국 각지의 수풀 속의 음습한 땅에 자라는 미나리아재비과의 동속근연식물의 다년생 초분식물의 뿌리를 일컫는 것으로서, 일명 '진범' 또는 '오독도기'라고도 하며 가을에 채취하여 경엽, 수염뿌리를 제거하고 깨끗이 썰어서 햇볕에 말린 것을 약제로 사용하여온 무독한 한방 생약이다. 한방에서는 예로부터 상기 동속근연식물을 진통(鎭痛), 진경(鎭痙), 풍습비통(風濕痺痛), 관절염, 황저(黃疽) 및 소변불리(小便不利) 등의 치료에 사용하여 왔는데, 최근에는 상기 약효 이외에도 혈압 강하, 각종 감염증에 대한 항균 작용, 진통 및 부신 피질 자극 호르몬 분비 증가에 의한 염증에도 약효가 있는 것으로 알려져 있다. 상기 진교 및 동속근연식물에 함유된 유효 성분으로는 라이콕토닌(lycoctonine), 아바드하리딘(avadharidine), 셉텐트리오딘(septentriodine)이 알려져 있으며, 이외에는 겐티아닌(gentianine), 겐티아니신(gentoianicine) 등의 알카로이드류와 메틸-n-(3-카바모일프로피오닐)안트라니레이트, 메틸-n-(2-아세트아미노벤조일)안트라니레이트 등의 방향족 화합물이 알려져 있다[도해향약 대사전, 영림사, p477∼478 (1990); 중약대사전, 도서출판정담, p5171∼5177 (1998)].Jinkyo refers to the roots of perennial herbaceous plants of the cognate plant of the genus Ranunculus, which grows in the dense ground in the bushes all over Korea. It is a toxic herbal medicine that has been cut and dried in the sun and used as a medicine. In oriental medicine, the same plant has been used for the treatment of analgesic, dysmenorrhea, customs pain, arthritis, yellowing, and urinary bulge. In recent years, in addition to the above-mentioned effects, it is known to have an effect on lowering blood pressure, antibacterial action against various infectious diseases, analgesic and inflammation due to increased secretion of corticosteroids. Lycoctonine, abadharidine, septinriodine are known as active ingredients contained in the orthodontic and cognate root plant, and other than gentianine and gentoianicine. Alkaloids, such as, and aromatic compounds, such as methyl-n- (3-carbamoyl propionyl) anthranilate and methyl-n- (2-acetaminobenzoyl) anthranilate, are known. , p477-478 (1990); Chinese Medicine Dictionary, Book Publishing Decision, p5171-5177 (1998)].

진교 추출물의 약효에 관해서는 동의보감, 향약집성방 및 광제비급 등의 기성 한외서 및 관련 문헌에 고전적 방법인 탕제 방식에 의하여 제조한 진교 추출물의 한방 의학적 약효가 일부 기재되어 있을 뿐, 상기 진교의 약효, 유효 활성 성분에 관한 분석적 연구 및 유효 활성 성분의 효율적인 추출 방법에 대한 연구는 극히 미미한 실정이며, 약효 성분이 다량 함유된 분획의 효율적인 추출 방법에 관해서는 현재까지 연구 발표된 바 없다.Regarding the medicinal properties of jinkyo extract, the traditional herbal medicines such as Dongbobogam, medicinal herb and medicinal herb, and related literature only describe some of the herbal medicinal medicinal effects of jinkyo extract prepared by the traditional method of medicinal herbs. Analytical studies on the active ingredients and studies on efficient extraction methods of the active ingredients are very small, and there have been no studies published on the efficient extraction methods of fractions containing a large amount of the active ingredient.

이에 본 발명자들은 소염 진통 작용을 가질 뿐만 아니라 풍, 한, 습으로 인한 비증을 개선시키는 것으로 알려진 진교를 보다 과학적으로 이용하고자 간단한 제조 방법에 의하여 진교 분획을 분리 제조하였고, 상기 분획물이 우수한 소염 진통 활성을 가지고 있음을 알게 되어 본 발명을 완성하였다. 본 발명은 진교로부터 소염 진통 활성이 우수한 분획물의 간단한 제조 방법과 이 분획물을 이용한 소염 진통제로의 이용을 제공하는데 그 목적이 있으며, 또한 본 발명들은 지금까지 한약탕제 등의 형태로만 국한되어 사용되어 왔던 진교 추출물을 투여가 간편한 정제 및 주사제의 제형으로 개발함으로써 본 발명을 완성하였다.Therefore, the present inventors separated and prepared the shingles fraction by a simple manufacturing method in order to use more scientifically known anti-inflammatory effect not only to have anti-inflammatory analgesic effect, but also to improve nasal sensation due to wind, cold, and wet, and the fraction has excellent anti-inflammatory analgesic activity. It was found that the present invention has been completed. The present invention has a purpose of providing a simple method for producing an excellent anti-inflammatory analgesic activity from Jingyo and its use as an anti-inflammatory analgesic agent using this fraction, and the present invention has been used only in the form of medicinal herbs, etc. The present invention has been completed by developing the extract of jinhwa into a formulation of tablets and injections for easy administration.

본 발명은 진교를 물 또는 알콜성 수용액으로 추출하여 진교 생약제를 제조함에 있어서,The present invention in the preparation of Chinese herbal medicines by extracting the Chinese onions with water or alcoholic aqueous solution,

상기 진교를 물로 추출 여과하는 단계와;Extracting and filtering the fibrils with water;

상기 추출 여과 단계에서 얻어진 여액을 여액 1 중량부에 대하여 0.7 ∼ 1.2 중량부의 수포화 저급 알콜로 층분리하는 단계와;Separating the filtrate obtained in the extraction filtration step with 0.7 to 1.2 parts by weight of a saturated lower alcohol with respect to 1 part by weight of the filtrate;

상기 층분리 단계에서 얻어진 잔여 수용액에 잔여수용액 1 중량부에 대하여 3 ∼ 5 중량부의 에틸 알콜을 가하여 여과한 여액을 60 ∼ 70℃의 온도에서 감압 농축하는 단계와;Concentrating the filtrate under reduced pressure at a temperature of 60 to 70 ° C. by adding 3 to 5 parts by weight of ethyl alcohol to 1 part by weight of the residual aqueous solution to the remaining aqueous solution obtained in the layer separation step;

상기 감압 농축 단계에서 얻어진 엑기스를 동결 건조하여 분말 엑기스를 제조하는 단계로 이루어진 것을 그 특징으로 한다.It characterized by consisting of a step of producing a powder extract by freeze drying the extract obtained in the vacuum concentration step.

또한, 본 발명은 상기 진교 추출물에 대한 분말 엑기스를 유효 성분으로 함유하는 소염 진통제와 이를 이용한 소염 진통 정제 및 주사제를 또 다른 특징으로 한다.In addition, the present invention is another feature of the anti-inflammatory analgesic containing a powder extract for the extract, as an active ingredient, and an anti-inflammatory analgesic tablet and injection using the same.

이와 같은 본 발명을 더욱 상세하게 설명하면 다음과 같다. The present invention will be described in more detail as follows.

본 발명은 상기 진교로부터 유효 활성 성분을 높은 효율로 추출할 수 있는 추출 방법과 상기 유효 활성 성분을 함유하는 소염 진통제, 또한 이를 이용한 정제 및 주사제를 그 특징으로 한다.The present invention is characterized by an extraction method capable of extracting the active active ingredient from the nebula with high efficiency and an anti-inflammatory analgesic agent containing the active active ingredient, as well as tablets and injections using the same.

우선, 상기 진교를 물로 추출 여과한다.First, the above-mentioned ointment is extracted and filtered with water.

상기 추출 여과는 진교 1 중량부에 대하여 8 ∼ 12 중량부의 물을 가하여 5시간 정도 환류 추출한 후 여과하여 여액을 모으고, 다시 잔사에 진교 1 중량부에 대하여 3 ∼ 7 중량부의 물을 가하고 가온하여 여과한 다음, 이전의 여액과 혼합함으로써 추출 효율을 높인다. 이때, 물의 양이 상기 범위 미만이면 교반이 어렵게 되고 추출물의 용해도가 낮아져 추출 효율이 떨어지게 되며, 물의 양이 상기 범위를 초과하면 다음 정제 단계에서 사용되는 수포화 저급 알콜 용매의 사용량이 많아져 경제적이지 못하며 취급상의 문제가 발생하게 된다.The extraction filtration was performed by adding 8 to 12 parts by weight of water to 1 part by weight of the duct and reflux extraction for 5 hours, then filtrating to collect the filtrate, and again adding 3 to 7 parts by weight of water to 1 part by weight of the duct to the residue and filtering by heating. Then, the extraction efficiency is increased by mixing with the previous filtrate. At this time, if the amount of water is less than the above range, the stirring becomes difficult and the solubility of the extract is lowered, the extraction efficiency is lowered. If the amount of the water exceeds the above range, the amount of the saturated low alcohol solvent used in the next purification step is increased and economical. And problems with handling occur.

본 발명에서는 1차 추출 후 다시 재추출하는 방법을 채택하였는데, 이는 추출 효율을 높이기 위한 것으로서 진교 추출물을 대량으로 생산하는 경우 효과적으로 여과를 한다고 하더라도 생약 자체의 수분 함량이 높기 때문에 손실이 발생하게 되어 1차 추출만으로는 추출 효과가 떨어지게 되므로 이를 방지하기 위함이다. 각 단계별 추출 효율을 검증한 결과 2차 추출에 의해 전체 추출량의 약 90% 정도가 추출되는 것으로 밝혀졌고, 따라서 3차 이상의 다단계 추출은 경제성이 없다.In the present invention, a method of re-extracting after the first extraction is adopted. This is to increase the extraction efficiency. However, when the bulky extract is produced in large quantities, even though it is effectively filtered, the loss occurs because the water content of the herbal medicine is high. Tea extraction alone is to reduce the extraction effect is to prevent this. As a result of verifying the extraction efficiency of each step, it was found that about 90% of the total extraction amount is extracted by the second extraction, and therefore, the third or more multistep extraction is not economical.

상기 추출 여과 단계에서 얻어진 여액을 여액 1 중량부에 대하여 0.7 ∼ 1.2중량부의 수포화 저급 알콜로 층분리한다.The filtrate obtained in the extraction filtration step is separated into 0.7 to 1.2 parts by weight of a saturated lower alcohol with respect to 1 part by weight of the filtrate.

상기와 같이 1, 2차에 걸쳐 물로 추출하여 얻은 추출액은 여과한 다음 여액 중에 함유된 불필요한 지방류 및 저분자 비극성 물질 등의 불순물을 정제하는데, 본 발명에서는 여액 1 중량부에 대하여 0.7 ∼ 1.2 중량부의 수포화 저급 알콜로 2 ∼ 3회 층분리를 실시하여 용매 분획을 제거함으로써 불순물을 정제한다. 본 발명에서는 상기 수포화 저급 알콜로서 수포화 부틸 알콜 또는 수포화 프로필 알콜을 사용할 수 있으며, 본 발명에서는 수포화 부틸 알콜을 사용하는 것이 바람직하다.As described above, the extract obtained by extraction with water in the first and second stages is filtered and purified from impurities such as unnecessary fats and low molecular weight nonpolar substances contained in the filtrate, and in the present invention, 0.7 to 1.2 parts by weight per 1 part by weight of the filtrate. The impurities are purified by performing layer separation two to three times with saturated lower alcohol to remove the solvent fraction. In the present invention, a saturated butyl alcohol or a saturated propyl alcohol can be used as the saturated lower alcohol, and it is preferable to use a saturated butyl alcohol in the present invention.

상기 수포화 저급 알콜의 사용량이 여액 1 중량부에 대하여 0.7 중량부 미만이면 정제 효율이 급격히 떨어지게 되고, 상기 수포화 저급 알콜의 사용량이 여액 1 중량부에 대하여 1.2 중량부를 초과하면 불필요한 저급 알콜 사용량 증가로 경제성이 떨어지게 되므로 정제 효과를 효율적으로 유지하기 위해서는 여액과 동량의 수포화 저급 알콜 용매로 2회 정도 층분리하는 것이 가장 바람직하다.If the amount of the saturated lower alcohol is less than 0.7 parts by weight based on 1 part by weight of the filtrate, the purification efficiency is drastically reduced. When the amount of the saturated lower alcohol exceeds 1.2 parts by weight based on 1 part by weight of the filtrate, the amount of unnecessary lower alcohol is increased. In order to maintain the purification effect efficiently, it is most preferable to separate the filtrate and two times with an equivalent amount of a saturated low alcohol solvent.

상기 층분리 단계에서 얻어진 잔여 수용액에 잔여수용액 1 중량부에 3 ∼ 5 중량부의 에틸 알콜을 가하여 여과한 여액을 감압 농축한다.The filtrate was concentrated under reduced pressure by adding 3 to 5 parts by weight of ethyl alcohol to 1 part of the residual aqueous solution to the remaining aqueous solution obtained in the layer separation step.

상기 층분리 단계에서 얻어진 잔여 수용액, 즉 수포화 저급 알콜을 사용하여 지방류 및 저분자 비극성 물질 등의 불순물을 정제한 수용액에 잔여 수용액 1 중량부에 3 ∼ 5의 중량부로 에틸 알콜을 가하여 상기 용액을 75 ∼ 83%(V/V)의 에탄올 수용액으로 조절하는데, 만일 상기 에틸 알콜의 사용량이 잔여 수용액 1 중량부에 대하여 3 중량부 미만이면 불순물인 일부 단백 다당류 및 다당류의 제거가 효율적으로 이루어지지 않아 독성이 증가하고 활성이 저하되며, 상기 에틸 알콜의 사용량이 잔여 수용액 1 중량부에 대하여 5 중량부를 초과하면 일부 유효 활성 성분도 함께 침전으로 제거되어 생리 활성이 저하되므로 바람직하지 않다. 잔여 수용액에 에틸 알콜을 가하여 얻어진 상기 여액을 유리 필터로 여과한 여액을 50 ∼ 60℃의 온도에서 감압 농축하는데, 만일 감압 농축 온도가 상기 범위를 벗어나면 농축 효율이 저하되거나 유효 활성 성분이 과도한 열에 노출되어 분해됨으로써 활성이 저하되므로 바람직하지 않다.Ethyl alcohol was added to 3 parts by weight of 1 to 5 parts by weight of the remaining aqueous solution to the remaining aqueous solution obtained in the step of separating the layer, that is, an aqueous solution in which impurities such as fatty acids and low molecular weight nonpolar substances were purified using a saturated lower alcohol. If the amount of the ethyl alcohol is less than 3 parts by weight based on 1 part by weight of the remaining aqueous solution, some protein polysaccharides and polysaccharides that are impurities are not efficiently removed and are toxic. This increases and decreases in activity, and when the amount of the ethyl alcohol used exceeds 5 parts by weight with respect to 1 part by weight of the residual aqueous solution, some of the active ingredients are also removed by precipitation, which is undesirable since the physiological activity is reduced. The filtrate obtained by adding ethyl alcohol to the remaining aqueous solution was concentrated under reduced pressure at a temperature of 50 to 60 ° C., if the reduced concentration was outside the above range, the concentration efficiency decreased or the active active ingredient was exposed to excessive heat. It is not preferable because the activity is degraded by exposure and decomposition.

상기 감압 농축 단계에서 얻어진 엑기스를 동결 건조하여 분말 엑기스를 제조한다.The extract obtained in the vacuum concentration step is freeze-dried to prepare a powder extract.

상기와 같은 방법으로 진교로부터 추출된 분말 엑기스를 HPLC를 이용하여 분석한 결과 도 1과 같은 결과를 나타내었으며, 상기 진교 추출물을 크로톤-오일(croton-oil) 유도 마우스 귀 부종법, 캬라기난(carrageenan) 유도 랫트 뒷발 부종법 및 초간 유도 마우스 비틀기(writhing)의 방법으로 시험한 결과, 상기 진교 추출물에 소염 진통 효과가 있음을 확인할 수 있었다.As a result of analyzing the powder extract extracted from orthogonal acid by HPLC using the same method as shown in FIG. 1, the orthodontic extract was treated with croton-oil-induced mouse ear edema, carrageenan. Induced rat hind edema and seconds of induced mouse writhing test results, it was confirmed that the anti-inflammatory analgesic effect on the extracts.

본 발명에서 얻어진 분말 엑기스를 함유하여 통상의 제조 방법으로 제형화하여 정제 및 주사제 등을 제조하는데, 이때 사용되는 기제, 예컨대 락토오스(lactose), 미세결정 셀룰로오즈(microcrystalline cellulose), 마그네슘 스테아레이트(magnesium stearate) 등의 기제 성분과 진교 분말 엑기스를 혼합하여 사용하면 소염 진통 효과를 더욱 상승시킬 수 있다. 특히, 본 발명의 생약 조성물을 인체에 투여하는 경우, 상기 진교가 천연 추출물임에 따라 기타 합성 의약품과 비교하여 부작용이 거의 없을 뿐만 아니라, 실제 독성 시험 결과에서도 생체에 아무런 부작용이 없는 것으로 나타났다.It contains the powder extract obtained in the present invention and is formulated by a conventional manufacturing method to prepare tablets and injections, etc. The bases used at this time, such as lactose, microcrystalline cellulose, magnesium stearate The anti-inflammatory analgesic effect can be further enhanced by using a mixture of base ingredients such as) and the powdered powder extract. In particular, when the herbal composition of the present invention is administered to the human body, since the dermis is a natural extract, as well as the side effects compared to other synthetic drugs, there are almost no side effects, even in actual toxicity test results.

상술한 바와 같이 본 발명에 따라 추출, 정제된 진교 추출물은 진교를 열탕 추출하는 종래의 방법으로 얻어진 추출물과 비교하여 그 효능면에서 현격한 차이가 있다. 또한, 종래 한약탕제 등의 형태로만 국한되어 사용되어 왔던 진교 추출물을 투여가 간편한 정제 및 주사제의 제형으로 제조할 수 있도록 하였다.As described above, the extract extracted and purified in accordance with the present invention has a marked difference in efficacy in comparison with the extract obtained by the conventional method of extracting boiling water from Jingyo. In addition, the traditional Chinese herbal medicines can be prepared in the form of tablets and injections easy to administer the extract of Jingyo, which has been used only in the form of herbal medicines.

이와 같은 본 발명을 실시예에 의거하여 상세히 설명하면 다음과 같은 바, 본 발명이 실시예에 한정되는 것은 아니다.If the present invention will be described in detail based on the embodiment as follows, the present invention is not limited to the embodiment.

실시예 1Example 1

시중에서 구입된 진교 1㎏에 12ℓ의 물을 가하여 5시간 동안 환류 추출한 후 여과하고, 잔사에 다시 5ℓ의 물을 가하여 추출하고 여액을 혼합한 후, 여액 중량의 1.2배의 수포화 n-부틸 알콜을 가하여 3회 층분리하였다. 층분리후 남은 수용액에 상기 수용액 부피의 4배의 에틸 알콜을 적가하여 불용 성분을 제거하고, 그 상등액을 55℃의 온도에서 감압 농축하고 동결 건조하여 464g의 분말 엑기스를 얻었다. 또한 얻어진 분말 엑기스에 대해서는 다음과 같은 조건하에서 고속 액체 크로마토그래피(HPLC)를 수행하였고, 그 결과를 도 1로 첨부하였다.12 l of water was added to 1 kg of commercially available oak and extracted under reflux for 5 hours, followed by filtration, and 5 liters of water was added to the residue, followed by extraction. The filtrate was mixed, and then 1.2 times the amount of saturated n-butyl alcohol in the filtrate. Layer was added three times. To the remaining aqueous solution after layer separation, ethyl alcohol four times the volume of the aqueous solution was added dropwise to remove insoluble components. The supernatant was concentrated under reduced pressure at a temperature of 55 ° C. and freeze-dried to obtain 464 g of a powder extract. In addition, the powder extract obtained was subjected to high performance liquid chromatography (HPLC) under the following conditions, and the results are attached to FIG. 1.

칼럼(column) : μ-Bondapak C18 (3.9×300㎜)Column: μ-Bondapak C 18 (3.9 × 300 mm)

이동상 : 물/메탄올/초산=8/2/0.05Mobile phase: water / methanol / acetic acid = 8/2 / 0.05

검출기 : UV 254㎚Detector: UV 254 nm

실시예 2Example 2

시중에서 구입한 잘 건조된 상태의 진교 1 ㎏에 8ℓ의 물을 가하여 4시간 동안 환류 추출한 후 여과하고, 잔사에 다시 3ℓ의 물을 가하여 추출하고 여액을 혼합한 후, 여액 중량의 0.7배의 수포화 n-부틸 알코올을 가하여 3회 층분리하였다. 층분리 후 남은 수용액에 상기 수용액 부피의 3배의 에틸 알콜을 적가하여 불용 성분을 제거하고, 그 상등액을 53℃의 온도에서 감압 농축하고 동결 건조하여 400g의 분말엑기스를 얻었다.8 ℓ of water was added to 1 kg of well-dried jinchuan, which was commercially available, and refluxed for 4 hours, filtered. The residue was added again with 3 ℓ of water, and the filtrate was mixed. The filtrate was 0.7 times the weight of the filtrate. Saturated n-butyl alcohol was added and the layers were separated three times. To the remaining aqueous solution after layer separation, ethyl alcohol three times the volume of the aqueous solution was added dropwise to remove insoluble components, and the supernatant was concentrated under reduced pressure at a temperature of 53 ° C and freeze-dried to obtain 400 g of powder extract.

실시예 3Example 3

잘 건조된 상태의 진교 1 ㎏을 수돗물로 세척하여 협잡물을 제거한 후 10ℓ의 물을 가하여 3시간 동안 환류 추출한 후 여과하고, 잔사에 다시 7ℓ의 물을 가하여 추출하고 여액을 혼합한 후, 여액과 동량의 수포화 n-부틸 알콜을 가하여 3회 층분리하였다. 층분리 후 남은 수용액에 상기 수용액 부피의 5배의 에틸 알콜을 적가하여 불용 성분을 제거하고, 그 상등액을 60℃의 온도에서 감압 농축하고 동결 건조하여 527g의 분말 엑기스를 얻었다.1 kg of well-dried jinchuan was washed with tap water to remove contaminants. 10 l of water was added thereto, followed by extraction under reflux for 3 hours, followed by filtration. 7 L of water was added to the residue, and the filtrate was mixed. Of saturated n-butyl alcohol was added and the layers were separated three times. Elution component was removed by dropwise addition of ethyl alcohol 5 times the volume of the aqueous solution to the remaining aqueous solution after layer separation, the supernatant was concentrated under reduced pressure at a temperature of 60 ℃ and lyophilized to give 527 g of powder extract.

비교예 1Comparative Example 1

시중에서 구입한 진교를 표준 탕액법으로 물 추출하였고, 상기 추출액을 여과하여 얻은 여액을 동결 건조하여 분말 엑기스를 얻었다.Commercially purchased jinkyo was extracted with water using a standard solution solution, and the filtrate obtained by filtration was freeze-dried to obtain a powder extract.

비교예 2Comparative Example 2

상기 비교예 1과 동일한 방법으로 물 추출하였고, 상기 추출액을 여과하여 얻은 여액을 동량의 수포화 n-부틸 알콜로 3회 층분리한 후, n-부틸 알코올층 만을 모아 65℃의 온도에서 감압 농축하고 물로 공비 농축하였고, 최종적으로 동량의 증류수를 가하여 현탁시킨 후 동결 건조하여 분말 엑기스를 얻었다.Water extraction was carried out in the same manner as in Comparative Example 1, and the filtrate obtained by filtration was separated three times with the same amount of saturated n-butyl alcohol, and only the n-butyl alcohol layer was collected and concentrated under reduced pressure at a temperature of 65 ° C. The mixture was concentrated azeotropically with water, and finally, the same amount of distilled water was added and suspended, followed by freeze drying to obtain a powder extract.

비교예 3Comparative Example 3

상기 비교예 1과 동일한 방법으로 물 추출하였고, 상기 추출액을 여과하여 얻은 여액을 동량의 수포화 n-부틸 알코올로 3회 층분리한 후, 상기 여액에 10ℓ의 에틸 알콜을 적가하여 생성된 침전물을 건조하여 분말 엑기스를 얻었다.Water extraction was performed in the same manner as in Comparative Example 1, and the filtrate obtained by filtering the extract was separated three times with the same amount of saturated n-butyl alcohol, and then the precipitate formed by dropwise addition of 10 L of ethyl alcohol to the filtrate. It dried and the powder extract was obtained.

제제예 1Formulation Example 1

상기 실시예 1에 의해 제조된 분말 엑기스를 이용하여 다음과 같은 조성으로 경구 투여용 정제를 제조하였다.Using the powder extract prepared in Example 1 to prepare a tablet for oral administration in the following composition.

〈 조성 〉< Furtherance >

실시예 1 분말엑기스 200 ㎎Example 1 200 mg powder extract

락토오스 60 ㎎Lactose 60 mg

마그네슘 스테아린산 40 ㎎Magnesium Stearate 40mg

미세분말 셀룰로오스 60 ㎎Fine powder cellulose 60 mg

옥수수 전분 40 ㎎Corn starch 40 mg

아에로실 30 ㎎Aerosil 30 mg

아비셀(PH-102) 70 ㎎Avicel (PH-102) 70 mg

제제예 2Formulation Example 2

상기 실시예 1에 의해 제조된 분말 엑기스를 다음과 같은 조성으로 주사제를 제조하였다.The powder extract prepared according to Example 1 was prepared in the following composition with the following composition.

〈 조성 〉< Furtherance >

주 사 용 앰 플 : 실시예 1 분말엑기스 200 ㎎Injection ampoule: Example 1 powder extract 200 mg

만니톨 360 ㎎                        Mannitol 360 mg

대응하는 용매 앰플 : Na2HPO4·12H2O 52 ㎎Corresponding Solvent Ampoule: Na 2 HPO 4 12H 2 O 52 mg

주사용 물 2974 ㎎                        2974 mg of water for injection

실험예 1Experimental Example 1

상기 실시예 1 및 비교예 1 ∼ 3에 의해 제조된 엑기스의 급성 소염 활성 비교로서 마우스 귀 부종 테스트를 다음과 같이 실시하였고, 그 결과를 도 2로 나타내었다.As a comparison of the acute anti-inflammatory activity of the extract prepared in Example 1 and Comparative Examples 1 to 3, the mouse ear edema test was performed as follows, and the results are shown in FIG. 2.

실험방법 : ICR(Institute of Cancer Research)계 마우스에 실시예 1 및 비교예 1 ~ 3에서 얻어진 진교추출물을 경구투여하고 1시간 후 2.5 % 크로톤 오일(croton oil)을 오른쪽 귀에 바르고 4시간 후 각각의 귀두께를 두께측정기(Dial thickness gauge)로 측정하였다. 대조군은 진교 추출물 대신 멸균 증류수를 경구 투여하였다.Experimental method: Oral administration of the extract from Examples 1 and 3 to ICR (Institute of Cancer Research) mice 1 hour after applying 2.5% croton oil (right) to the right ear and after 4 hours each Ear thickness was measured with a dial thickness gauge. The control group was orally administered sterile distilled water in place of the extract.

도 2에서 알 수 있듯이, 본 발명의 추출물이 투여된 실시예 1의 경우가 염증에 대한 억제 효율이 가장 높다.As can be seen in Figure 2, the case of Example 1 to which the extract of the present invention is administered has the highest inhibition efficiency against inflammation.

실험예 2Experimental Example 2

상기 실시예 1 및 비교예 1 ∼ 3에 의해 제조된 엑기스의 급성 소염 활성 비교로서 랫트 뒷발 부종 테스트를 다음과 같이 실시하였으며, 그 결과를 다음 표 1에 나타내었다.Rat hind paw edema test was performed as a comparison of the acute anti-inflammatory activity of the extract prepared by Example 1 and Comparative Examples 1 to 3, the results are shown in Table 1 below.

실험방법 : SD(Spraque-Dawley)계 랫트에 상기 실시예 1 및 비교예 1 ∼ 3에 의해 제조된 각각의 진교 추출물을 정맥 주사하고 15분 후 1 % 캬라기난용액 0.1 ㎖(1 % carrageenan in saline solution)를 랫트의 뒤쪽 왼발에 피하 주사한 후 5 시간 동안 2 시간 간격으로 부피 측정기(UGOBASILE TYPE 7150)을 사용하여 좌측 뒷발의 부종을 측정하였다. 대조군으로는 진교추출물 대신 멸균 생리 식염수를 정맥 주사하였다.Experimental Method: After 15 minutes of intravenous injection of each of the extracts prepared by Examples 1 and 3 into SD (Spraque-Dawley) rats, 0.1 ml of 1% carrageenan solution (1% carrageenan in saline) solution) was injected subcutaneously into the rear left foot of the rat and the edema of the left hind paw was measured using a volumetric meter (UGOBASILE TYPE 7150) at a 2-hour interval for 5 hours. As a control, sterile saline was injected intravenously in place of the extract.

[표 1]TABLE 1

상기 표 1의 결과로부터 알 수 있듯이, 본 발명의 추출물이 투여된 실시예 1의 경우가 염증에 대한 억제 효율이 가장 높다.As can be seen from the results of Table 1, the case of Example 1 to which the extract of the present invention is administered has the highest inhibition efficiency against inflammation.

실험예 3Experimental Example 3

상기 실시예 1 및 비교예 1 ∼ 3에 의해 제조된 엑기스의 진통 작용 효력 비교로서 초산 유도 마우스 비틀기 테스트를 다음과 같이 실시하였으며, 그 결과를 다음 표 2에 나타내었다.Acetic acid induced mouse twist test was performed as a comparison of the analgesic effect of the extract prepared in Example 1 and Comparative Examples 1 to 3 as follows, the results are shown in Table 2 below.

실험방법 : ICR계 마우스에 상기 실시예 1 및 비교예 1 ∼ 3에 의해 제조된 각각의 진교 추출물을 경구투여하고, 1시간 후 0.6% 초산을 마우스 몸무게 10g당 0.1㎖의 용량으로 복강주사하고, 주사 후 10분 후부터 10분간 각각의 마우스가 나타내는 통증 반응인 비틀기(writhing : 등을 쭉 펴거나 뒷다리를 몸 뒤로 완전히 뻗어 제치는 현상)를 보이는 횟수를 관찰하였다. 대조군은 진교 추출물 대신 멸균 증류수를 경구투여하였다.Experimental method: Orally administered to each of the extracts prepared in Example 1 and Comparative Examples 1 to 3 ICR mice, and after 1 hour 0.6% acetic acid was intraperitoneally injected at a dose of 0.1ml per 10g of mouse weight, 10 minutes after the injection, the number of times of writhing (writhing: stretching the back or stretching the hind legs completely) was observed. The control group was orally administered sterile distilled water in place of the extract.

[표 2]TABLE 2

상기 표 2의 결과로부터 알 수 있듯이, 본 발명의 추출물이 투여된 실시예 1의 경우가 진통 작용이 가장 우수함을 알 수 있다.As can be seen from the results of Table 2, it can be seen that in the case of Example 1 to which the extract of the present invention is administered, the analgesic action is the best.

실험예 4Experimental Example 4

상기 실시예 1에서 얻어진 분말 엑기스를 6.00g/㎏의 투여 용량으로 ICR계 마우스에 정맥 투여하고 2주일 동안 관찰한 결과 폐사되는 동물은 나타나지 않았으며, 기타 해부학적 소견에 있어서도 대조군과 비교하여 아무런 이상이 발견되지 않았고, 이를 통해 상기 실시예 1에서 얻은 분말 엑기스가 극히 안전한 물질이라는 것을 알 수 있었다.When the powder extract obtained in Example 1 was administered intravenously to an ICR mouse at a dose of 6.00 g / kg and observed for two weeks, no animals were found to be dead, and other anatomical findings were not abnormal compared to the control group. Was not found, and it was found that the powder extract obtained in Example 1 was an extremely safe substance.

상술한 바와 같이 본 발명에 따라 추출, 정제된 진교 추출물은 진교를 열탕 추출하는 종래의 방법으로 얻어진 추출물과 비교하여 그 효능면에서 현격한 차이가 있으며, 또한 종래 한약탕제 등의 형태로만 국한되어 사용되어 왔던 진교 추출물을 정제 및 주사제의 제형으로 제조함으로써 복용을 훨씬 간편하게 하였다.As described above, the extract extracted and purified according to the present invention has a marked difference in efficacy compared to the extract obtained by the conventional method of extracting boiling water from Jingyo, and it is also limited to only conventional herbal medicines and the like. The dosage has been made much simpler by preparing the powdered extracts that have been used in the formulation of tablets and injections.

도 1은 실시예 1에 의해 제조된 진교 추출물의 고속 액체 크로마토그래피(HPLC)결과이며, 1 is a result of high performance liquid chromatography (HPLC) of the extract of Jinkyo prepared by Example 1,

도 2는 실시예 1 및 비교예 1 ∼ 3에 의해 제조된 진교 추출물의 크로톤 오일(croton-oil)로 유도되는 귀부종의 억제 정도를 백분율로 나타낸 그래프이다.Figure 2 is a graph showing the percentage of inhibition of ear edema induced by croton-oil (croton-oil) of the extracts prepared by Examples 1 and Comparative Examples 1-3.

Claims (5)

진교를 물 또는 알콜성 수용액으로 추출하여 진교 생약제를 제조함에 있어서,In preparing the Chinese herbal medicine by extracting the Chinese herbal medicine with water or alcoholic aqueous solution, 상기 진교를 물로 추출 여과하는 단계와;Extracting and filtering the fibrils with water; 상기 추출 여과 단계에서 얻어진 여액을 여액 1 중량부에 대하여 0.7 ∼ 1.2 중량부의 수포화 저급 알콜로 층분리하는 단계와;Separating the filtrate obtained in the extraction filtration step with 0.7 to 1.2 parts by weight of a saturated lower alcohol with respect to 1 part by weight of the filtrate; 상기 층분리 단계에서 얻어진 잔여 수용액에 잔여수용액 1 중량부에 대하여 3 ∼ 5 중량부의 에틸 알콜을 가하여 여과한 여액을 60 ∼ 70℃의 온도에서 감압 농축하는 단계와;Concentrating the filtrate under reduced pressure at a temperature of 60 to 70 ° C. by adding 3 to 5 parts by weight of ethyl alcohol to 1 part by weight of the residual aqueous solution to the remaining aqueous solution obtained in the layer separation step; 상기 감압 농축 단계에서 얻어진 엑기스를 동결 건조하여 분말 엑기스를 제조하는 단계로 이루어진 것을 특징으로 하는 소염 및 진통 효과를 가지는 진교 추출물의 제조방법.Freeze-dried extract obtained in the step of concentration under reduced pressure to prepare a powder extract. 제 1 항에 있어서, 상기 추출 여과 단계는 진교 1 중량부에 대하여 8 ∼ 12 중량부의 물을 가하여 5시간 정도 환류 추출한 후 여과하여 여액을 모으고, 다시 잔사에 진교 1 중량부에 대하여 3 ∼ 7 중량부의 물을 가하고 가온하여 여과한 다음, 이전의 여액과 혼합하는 방법으로 수행됨을 특징으로 하는 제조방법.The method of claim 1, wherein the extraction filtration step is carried out by reflux extraction for about 5 hours by adding 8 to 12 parts by weight of water to 1 part by weight of pulverized, filtered to collect the filtrate, and 3 to 7 parts by weight based on 1 part by weight of pulverized Partial water, warmed and filtered, and then the mixture is carried out by mixing with the previous filtrate. 제 1 항에 있어서, 상기 수포화 저급 알콜은 수포화 부틸 알콜 또는 수포화 프로필 알콜인 것을 특징으로 하는 제조방법.2. A process according to claim 1, wherein the saturated lower alcohol is saturated butyl alcohol or saturated propyl alcohol. 제 1 항의 추출물에 대한 분말 엑기스를 유효성분으로 함유하는 소염진통제.Anti-inflammatory analgesic containing a powder extract of the extract of claim 1 as an active ingredient. 제 1 항의 추출물에 대한 분말 엑기스를 유효성분으로 하는 소염진통 정제 및 주사제.Anti-inflammatory analgesic tablets and injections comprising the powder extract of the extract of claim 1 as an active ingredient.
KR1019980060437A 1998-12-29 1998-12-29 Extraction and Purification of Active Active Ingredients from Jinkyo and Herbal Medicine Compositions Containing the Extracts KR100552991B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019980060437A KR100552991B1 (en) 1998-12-29 1998-12-29 Extraction and Purification of Active Active Ingredients from Jinkyo and Herbal Medicine Compositions Containing the Extracts

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019980060437A KR100552991B1 (en) 1998-12-29 1998-12-29 Extraction and Purification of Active Active Ingredients from Jinkyo and Herbal Medicine Compositions Containing the Extracts

Publications (2)

Publication Number Publication Date
KR20000043996A KR20000043996A (en) 2000-07-15
KR100552991B1 true KR100552991B1 (en) 2006-05-22

Family

ID=19567252

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019980060437A KR100552991B1 (en) 1998-12-29 1998-12-29 Extraction and Purification of Active Active Ingredients from Jinkyo and Herbal Medicine Compositions Containing the Extracts

Country Status (1)

Country Link
KR (1) KR100552991B1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070071357A (en) * 2005-12-30 2007-07-04 에스케이케미칼주식회사 An extract of gentianae macrophyllae radix for the treatment of dermatological disease
KR100720671B1 (en) * 2006-02-23 2007-05-21 경희대학교 산학협력단 The composition comprising extracts of gentiana scabra, citrus unshiu marcor and coptis chinensis for treatment of type iv allergy and an inflammation
WO2014166501A2 (en) 2013-04-10 2014-10-16 Skau Aps Use of immune suppressive peptides as adjuvants

Also Published As

Publication number Publication date
KR20000043996A (en) 2000-07-15

Similar Documents

Publication Publication Date Title
Shikov et al. Medicinal plants of the Russian Pharmacopoeia; their history and applications
CA2451740C (en) Composition comprising wenguanguo extracts, methods for preparing same and uses thereof
JP2006510592A (en) Extraction and purification method of active component of honeysuckle (LonicerajaponicaThumb.) Stem, its use for anti-inflammatory analgesic
Abd-Al-Sattar Sadiq Layl Hepatoprotective effect of Glycyrrhiza glabra L. extracts against carbon tetrachloride-induced acute liver damage in rats
AU2006209110B2 (en) Pharmaceutical composition for treating nephropathy and healthy food comprising herb extracts
CN101664482B (en) Externally-applied medicine for treating beriberi and skin pruritus and preparation method thereof
KR100552991B1 (en) Extraction and Purification of Active Active Ingredients from Jinkyo and Herbal Medicine Compositions Containing the Extracts
CN101982184A (en) Preparation method of taraxacum extract
KR0180567B1 (en) Method for extracting and purifying effective reactive from compound crude drug
JP5267885B2 (en) Pharmaceutical composition for prevention and / or treatment of inflammatory diseases, comprising a mixed extract of Tsukiishi wisteria and Ichiyakuso
Urabee et al. Extraction methods of Alhagi Maurorum (camel thorn) and its therapeutic applications
RU2213570C2 (en) Curative-prophylactic agent from linden leaves folia tilia and method for preparing extractive substances
CN103251908A (en) Hair-restorer and preparation method thereof
KR100672036B1 (en) Asthma Therapeutics using Lonicera japonica extracts
JP5030366B2 (en) Composition for treatment of allergic diseases
CN102895386B (en) Method for performing extraction on angelica dahurica, common cnidium fruit, Chinese red pepper and elecampane inula root and pharmaceutical application
KR0156039B1 (en) Pharmaceutical composition for hepatic disease
RU2665968C1 (en) Method for obtaining an agent of choleretic, anti-inflammatory and antioxidant activity
CN100528170C (en) Mangiferin preparation and production thereof
JP4979053B2 (en) Anticancer agent containing gentian extract, health supplement and medicinal cosmetic, and method for producing gentian extract
SK11142003A3 (en) Use of one or more shogaols as aphrodisiac(s)
KR0163813B1 (en) Process for extracting and purification method of pharmacologally effective components for capriofoliaceae and crude drug composition containing the extract
Ahmad et al. Kaiphal (Myrica nagi): A Botanical Origin Drug (Dawa) of Unani Medicine for Prevention and Treatment of Common Disorders
US20050118287A1 (en) Use of a vanilloid as an anti-snoring element
CN1045885C (en) Method for preparing stomatitis spray

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20130121

Year of fee payment: 8

FPAY Annual fee payment

Payment date: 20140121

Year of fee payment: 9

FPAY Annual fee payment

Payment date: 20150126

Year of fee payment: 10

FPAY Annual fee payment

Payment date: 20160120

Year of fee payment: 11

FPAY Annual fee payment

Payment date: 20170119

Year of fee payment: 12

LAPS Lapse due to unpaid annual fee